Biden administration to retire 'Operation Warp Speed' name
January 15, 2021 -- The incoming Biden administration said that it will no longer use the "Operation Warp Speed" term to describe the U.S. government's efforts to combat the COVID-19 pandemic.
Thermo Fisher closes Henogen acquisition
January 15, 2021 -- Thermo Fisher Scientific has closed its acquisition of Groupe Novasep's Henogen, a viral vector manufacturing business in Belgium, for approximately 725 million euros ($876 million U.S.) in cash.
Gamma Biosciences to acquire BioMagnetic Solutions
January 15, 2021 -- Gamma Biosciences has agreed to acquire BioMagnetic Solutions, a next-generation cell selection and bioseparation technology company.
RoosterBio, Sartorius partner on cell and gene therapy manufacturing
January 15, 2021 -- RoosterBio and Sartorius have signed a strategic collaboration to advance the scale-up of human mesenchymal stem/stromal cells manufacturing for regenerative medicines.
Fujifilm secures funding, signs lease for new research/manufacturing center
January 14, 2021 -- Fujifilm Diosynth Biotechnologies has announced $76 million in financing for the Center for Advanced Biological Innovation and Manufacturing and that a lease for a site in the Boston area has been signed.
Startup Creative Bio launches cell culture portfolio
January 14, 2021 -- Creative Bio has launched a portfolio of cell culture tools that it hopes will be useful during the COVID-19 pandemic.
Thermo Fisher subsidizes more sequencers for global coronavirus research
January 14, 2021 -- Thermo Fisher Scientific is expanding a global SARS-CoV-2 program that provides its next-generation sequencers at subsidized prices to help analyze new strains of the virus and for tracing community transmission.
Bone Therapeutics, Rigenerand partner on cell therapy process development
January 14, 2021 -- Bone Therapeutics and Rigenerand have formed a cell therapy process development partnership.
Cytovia licenses CAR NK tech to NCI
January 13, 2021 -- Cytovia Therapeutics has signed a licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to apply its gene-edited induced pluripotent stem cell-derived technology to develop glypican-3 (GPC3) chimeric antigen receptor (CAR) natural killer (NK) cell therapeutics.
LabCentral debuts platform to attract people to biotech
January 13, 2021 -- LabCentral has launched a platform that aims to broaden and diversify the biotech industry's base of talent.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter